UnicoCell Biomed Co., Ltd. (6794.TW) stock: key figures, P/E, revenue and dividend

Health Care · Taiwan

Price
67.70 TWD
Market cap
4.12 bn TWD
P/E (2025)
–
P/S (2025)
136.95
Dividend yield
0.00 %
Net margin
-381.48 %
Return on equity (ROE)
-13.27 %
Return on assets (ROA)
-12.14 %

UnicoCell Biomed Co., Ltd. financials

Fiscal year20242025
Revenue31.88 m TWD30.10 m TWD
Gross profit20.57 m TWD-221,000.00 TWD
Operating income-102.92 m TWD-130.28 m TWD
EBIT-91.61 m TWD-130.28 m TWD
Net income-93.07 m TWD-114.84 m TWD
Diluted EPS – continuing operations-1.57 TWD-1.89 TWD

Full history since 2017, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About UnicoCell Biomed Co., Ltd.

UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs in Taiwan and Japan. The company develops ELIXCYTE for the treatment of knee osteoarthritis and chronic kidney disease. It also operates an allogeneic adipose stem cell bank. In addition, the company offers autologous stem cell therapy; conditioned medium; UnicoVial, a cryogenic vial for the storage of cell products and biological samples under ultra-low temperature; and laboratory testing services, which include sterility, endotoxin, mycoplasma, and cell count and viability tests, as well as contract development and manufacturing organization (CDMO) services for cell-based products. UnicoCell Biomed Co., Ltd. was founded in 2011 and is based in Taipei, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.